Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interleukin-2 gene therapy (VCL-IM01)

Drug Profile

Interleukin-2 gene therapy (VCL-IM01)

Alternative Names: Electroporation-delivered DNA immunotherapy against metastatic melanoma - Inovio/Brickell Biotech Inc; IL-2 plasmid DNA/lipid complex (Leuvectin); IL-2-based DNA vaccine - Brickell Biotech Inc; IL-2/EP - Brickell Biotech Inc; Interleukin-2 gene therapy - Brickell Biotech Inc; VCL-1M01; VCL-IM01

Latest Information Update: 06 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vical
  • Developer Inovio Pharmaceuticals; Vical
  • Class Antineoplastics; Cytokine genes; Gene therapies; Interleukins
  • Mechanism of Action Gene transference; Immunostimulants; Interleukin 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Malignant melanoma; Prostate cancer; Renal cancer

Most Recent Events

  • 31 Aug 2019 Brickell Biotech has merged with Vical to form Brickell Biotech Inc, and subsequently Brickell Biotech changed its name to Brickell Subsidiary
  • 18 Dec 2008 Final efficacy and adverse events data from a phase I trial in Metastatic melanoma presented at the DNA Vaccines 2008 Conference (DNA Vaccines-2008)
  • 11 Jun 2007 Interim results from a phase I clinical trial in patients with Metastatic melanoma added to the adverse events and Cancer therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top